Vireo Growth (VREOF) Other Accumulated Expenses (2020 - 2025)

Vireo Growth (VREOF) reported Other Accumulated Expenses of $77128.0 for Q4 2025, down 83.93% sequentially from $479959.0 in Q3 2025.

Vireo Growth (VREOF) Other Accumulated Expenses (2020 - 2025) Analysis & Trends

Vireo Growth (VREOF) has 3 years of Other Accumulated Expenses data on file, last reported at $77128.0 in Q4 2025.

For the quarter ending Q4 2025, Other Accumulated Expenses changed N/A year-over-year to $77128.0; the trailing twelve-month figure through Dec 2025 stood at $77128.0 (changed N/A YoY), and the FY2025 full-year result was $77128.0, changed N/A from the prior year.
Other Accumulated Expenses declined to $77128.0 in Q4 2025, from $479959.0 in the prior quarter.
In the past five years, Other Accumulated Expenses ranged from a high of $720601.0 in Q3 2021 to a low of $77128.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Vireo Growth	10.57 Bn	10.41 Bn	59.30 Mn

Download Data